Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study

British Journal of Psychiatry

Volumn 173, Issue OCT., 1998, Pages 325-329

  Waddington, John L ^a   Youssef, Hanafy A ^a   Kinsella, Anthony ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; PHENOTHIAZINE;

ADJUVANT THERAPY; ADULT; AGED; ANTICHOLINERGIC EFFECT; ARTICLE; BRAIN SIZE; CARDIOVASCULAR DISEASE; DRUG WITHDRAWAL; EDENTULOUSNESS; FEMALE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTION; PSYCHOPHARMACOLOGY; RISK FACTOR; SCHIZOPHRENIA; SENESCENCE; SEX DIFFERENCE; SURVIVAL RATE;

EID: 0031668084     PISSN: 00071250     EISSN: None     Source Type: Journal    
DOI: 10.1192/bjp.173.4.325     Document Type: Article

References (27)

1. Allman, J., McLaughlin, T. & Hakeem, A. (1993) Brain structures and life-span in primate species. Proceedings of the National Academy of Sciences USA, 90, 3559-3563.
2. Barnes, T. R. E. (1990) Comment on the WHO consensus statement. British Journal of Psychiatry, 156, 413-414.
3. Brown, S. (1997) Excess mortality of schizophrenia. A meta-analysis. British Journal of Psychiatry, 171, 502-508.
4. Caldwell, C. B. & Gottesman, I. I. (1990) Schizophrenics kill themselves too: a review of risk factors for suicide. Schizophrenia Bulletin, 16, 571-589.
5. Department of Health (1995) Health Statistics 1993. Dublin: Stationery Office, Government of Ireland.
6. Dufresne, R. L. (1995) Psychiatric pharmacy research workshop: Issues in polypharmacotherapy. Psychopharmacology Bulletin, 31, 789-796.
7. Jablensky, A. (1995) Schizophrenia: the epidemiological horizon. In Schizophrenia (eds S. R. Hirsch & D. R. Weinberger), pp. 206-252. Oxford: Blackwell.
8. Joseph, K. S., Blais, L., Ernst, P., et al (1996) Increased morbidity and mortality related to asthma among asthmatic patients who use major tranquillisers. British Medical Journal, 312, 79-83.
9. Kane, J. M. (1795) Psychopharmacalogical approaches to schizophrenia: practical aspects. In Advances in the Neurobiology of Schizophrenia (eds J. A. Den Boer, H. G. M. Westenberg & H. M. Van Praag), pp. 245-263. Chichester: Wiley.
10. _ (1996) Drug therapy: schizophrenia. New England Journal of Medicine, 334, 34-41.
11. Licht, R. W., Mortensen, P. B., Gouliaev, G., et al (1993) Mortality in Danish psychiatric long-stay patients, 1972-1982. Acta Psychiatrica Scandinavica, 87, 336-341.
12. McKeith, I., Fairbairn, A., Perry, R., et al (1992) Neuroleptic sensitivity in patients with senile dementia of Lewy body type. British Medical Journal, 305, 673-678.
13. Naftdowitz, D. F., Donovan, S. & Frances, A. (1995) The new polypharmacy in psychiatry: clinical practice and clinical research part company. CNS Drugs, 4, 404-409.
14. Rakowski, W. & Mor, V. (1992) The association of physical activity with mortality among older adults in the longitudinal study of aging (1984-1988). Journal of Gerontology, 47, M122-M129.
15. Saku, M., Tokudome, S., Ikeda, M., et al (1995) Mortality in psychiatric patients, with a specific focus on cancer mortality associated with schizophrenia. International Journal of Epidemiology, 24, 366-372.
16. Stones, M. J., Dornan, B. & Kozma, A. (1989) The prediction of mortality in elderly institution residents. Journal of Gerontology, 44, P72-P79.
17. Waddington, J. L. (1992) Mechanisms of neuroleptic-induced extrapyramidal side effects. In Adverse Effects of Psychotropic Drugs (eds J. M. Kane & J. A. Lieberman), pp. 246-265. New York: Guilford Press.
18. _ (1993) Schizophrenia: developmental neuroscience and pathobiology. Lancet, 341, 531-536.
19. _ (1995) The clinical psychopharmacology of antipsychotic drugs in schizophrenia. In Schizophrenia (eds S. R. Hirsch & D. R. Weinberger), pp. 341-357. Oxford: Blackwell.
20. _, Youssef, H. A., Dolphin, C., et al (1987) Cognitive dysfunction, negative symptoms and tardive dyskinesia in schizophrenia. Archives of General Psychiatry, 44, 907-912.
21. _, _ & Kinsella, A. (1990) Cognitive dysfunction in schizophrenia followed up over five years, and its longitudinal relationship to the emergence of tardive dyskinesia. Psychological Medicine, 20, 835-842.
22. _, _ & _ (1995) Sequential cross-sectional and 10-year prospective study of severe negative symptoms in relation to duration of initially untreated psychosis in chronic schizophrenia. Psychological Medicine, 25, 849-857.
23. Weinberger, D. R. (1995) Schizophrenia: from neuropathology to neurodevelopment. Lancet, 346, 552-557.
24. Working Group of the Royal College of Psychiatrists, Psychopharmacology Sub-Group (1997) The Association Between Antipsychotic Drugs and Sudden Death. Council Report CR57. London: Royal College of Psychiatrists.
25. World Health Organization (1978) Mental Disorders: Glossary and Guide to their Classification in Accordance with the Ninth Revision of the International Classification of Diseases. (ICD-9). Geneva: WHO.
26. World Health Organization Heads of Centres Collaborating in WHO Coordinated Studies on Biological Aspects of Mental Illness (1990) Prophylactic use of anticholinergics in patients on long-term neuroleptic treatment. A consensus statement. British Journal of Psychiatry, 156, 412.
27. Yoneyama, T., Hashimoto, K., Fukuda, H., et al (1996) Oral hygiene reduces respiratory infections in elderly bed-bound nursing home patients. Archives of Gerontology and Geriatrics, 22, 11-19.